Table 1.

5-HTTLPR genotype frequencies by treatment and abstinence at 12-week and 24-week follow-ups.

	5-HTTLPR Genotype
	SS			SL			LL
	Active (n=72)	Placebo (n=59)	Combined (n=131)	Active (n=173)	Placebo (n=180)	Combined (n=353)	Active (n=125)	Placebo (n=132)	Combined (n=257)
12-Week
Succeeded	18 (25%)	7 (12%)	25 (19%)	33 (19%)	18 (10%)	51 (14%)	24 (19%)	18 (14%)	42 (16%)
Failed	54 (75%)	52 (88%)	106 (81%)	140 (81%)	162 (90%)	302 (86%)	101 (81%)	114 (86%)	215 (84%)
24-Week
Succeeded	12 (17%)	4 (7%)	16 (12%)	22 (13%)	12 (7%)	34 (10%)	23 (18%)	18 (14%)	41 (16%)
Failed	60 (83%)	55 (93%)	115 (88%)	151 (87%)	168 (93%)	319 (90%)	102 (82%)	114 (86%)	216 (84%)

Note. All values are numbers of subjects with percentages.